Ningke Biotech announced that revenue for the third quarter of 2026 was 136 million yuan, an increase of 22.08% over the previous year; the net profit loss attributable to shareholders of listed companies was 585.326 million yuan, after deducting a loss of 60.498 million yuan in non-net profit. Revenue for the first three quarters of 2026 was 411 million yuan, up 25.50% year on year; net profit loss attributable to shareholders of listed companies was 191 million yuan, after deducting loss of 193 million yuan in non-net profit. According to the company, the losses were mainly due to uncompleted technological transformation related to the Zhongke New Materials process, insufficient production capacity release, depreciation of fixed assets, and the inability to dilute fixed expenses such as depreciation of fixed assets and operating costs of public and auxiliary facilities.

Ningke Biotech announced that revenue for the third quarter of 2026 was 136 million yuan, an increase of 22.08% over the previous year; the net profit loss attributable to shareholders of listed companies was 585.326 million yuan, after deducting a loss of 60.498 million yuan in non-net profit. Revenue for the first three quarters of 2026 was 411 million yuan, up 25.50% year on year; net profit loss attributable to shareholders of listed companies was 191 million yuan, after deducting loss of 193 million yuan in non-net profit. According to the company, the losses were mainly due to uncompleted technological transformation related to the Zhongke New Materials process, insufficient production capacity release, depreciation of fixed assets, and the inability to dilute fixed expenses such as depreciation of fixed assets and operating costs of public and auxiliary facilities.